MARKET

INCY

INCY

Incyte Corp
NASDAQ
90.33
+0.03
+0.03%
Pre Market: 91.00 +0.67 +0.74% 07:33 03/31 EDT
OPEN
91.13
PREV CLOSE
90.30
HIGH
91.69
LOW
90.08
VOLUME
46
TURNOVER
0
52 WEEK HIGH
112.29
52 WEEK LOW
53.56
MARKET CAP
17.98B
P/E (TTM)
14.09
1D
5D
1M
3M
1Y
5Y
1D
Assessing Incyte (INCY) Valuation After Recent Share Price Weakness And Mixed Fair Value Signals
Simply Wall St · 10h ago
Incyte Announces Upcoming Resignation of Board Member Schaffert
TipRanks · 16h ago
Incyte director Susanne Schaffert resigns, effective April 15
Reuters · 18h ago
Analysts Offer Insights on Healthcare Companies: Lipocine (LPCN), Viridian Therapeutics (VRDN) and Incyte (INCY)
TipRanks · 1d ago
Guggenheim Sticks to Their Buy Rating for Incyte (INCY)
TipRanks · 1d ago
Stifel Nicolaus Keeps Their Buy Rating on Incyte (INCY)
TipRanks · 1d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (INCY), Sanofi (OtherSNYNF) and Johnson & Johnson (JNJ)
TipRanks · 1d ago
Weekly Report: what happened at INCY last week (0323-0327)?
Weekly Report · 1d ago
More
About INCY
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.

Webull offers Incyte Corp stock information, including NASDAQ: INCY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INCY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INCY stock methods without spending real money on the virtual paper trading platform.